FI973713A - Karboksi- tai tetratsolipääteryhmiä sisältävät dialkyylieetterit - Google Patents
Karboksi- tai tetratsolipääteryhmiä sisältävät dialkyylieetterit Download PDFInfo
- Publication number
- FI973713A FI973713A FI973713A FI973713A FI973713A FI 973713 A FI973713 A FI 973713A FI 973713 A FI973713 A FI 973713A FI 973713 A FI973713 A FI 973713A FI 973713 A FI973713 A FI 973713A
- Authority
- FI
- Finland
- Prior art keywords
- dialkyl ethers
- containing terminal
- ethers containing
- terminal carboxy
- tetrazole groups
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
- C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/28—Saturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
- C07C47/37—Saturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/305—Saturated compounds containing more than one carboxyl group containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/305—Saturated compounds containing more than one carboxyl group containing ether groups, groups, groups, or groups
- C07C59/315—Saturated compounds containing more than one carboxyl group containing ether groups, groups, groups, or groups containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/347—Saturated compounds containing more than one carboxyl group containing keto groups
- C07C59/353—Saturated compounds containing more than one carboxyl group containing keto groups containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/708—Ethers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pigments, Carbon Blacks, Or Wood Stains (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Medicinal Preparation (AREA)
- Dental Preparations (AREA)
- Absorbent Articles And Supports Therefor (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/409,780 US5648387A (en) | 1995-03-24 | 1995-03-24 | Carboxyalkylethers, formulations, and treatment of vascular diseases |
PCT/US1996/001639 WO1996030328A1 (en) | 1995-03-24 | 1996-02-05 | Terminal carboxy or tetrazole groups containing dialkyl ethers |
Publications (2)
Publication Number | Publication Date |
---|---|
FI973713A0 FI973713A0 (fi) | 1997-09-17 |
FI973713A true FI973713A (fi) | 1997-09-24 |
Family
ID=23621941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI973713A FI973713A (fi) | 1995-03-24 | 1997-09-17 | Karboksi- tai tetratsolipääteryhmiä sisältävät dialkyylieetterit |
Country Status (27)
Country | Link |
---|---|
US (4) | US5648387A (fi) |
EP (1) | EP0820428B1 (fi) |
JP (1) | JP3885115B2 (fi) |
KR (1) | KR100408612B1 (fi) |
CN (1) | CN1100747C (fi) |
AT (1) | ATE192732T1 (fi) |
AU (1) | AU692359B2 (fi) |
BG (1) | BG63534B1 (fi) |
CA (1) | CA2215233C (fi) |
CZ (1) | CZ289556B6 (fi) |
DE (1) | DE69608268T2 (fi) |
DK (1) | DK0820428T3 (fi) |
EE (1) | EE03520B1 (fi) |
ES (1) | ES2148733T3 (fi) |
FI (1) | FI973713A (fi) |
GR (1) | GR3034109T3 (fi) |
HK (1) | HK1009438A1 (fi) |
HU (1) | HUP9801825A3 (fi) |
NO (1) | NO307878B1 (fi) |
NZ (1) | NZ302170A (fi) |
PL (1) | PL181673B1 (fi) |
PT (1) | PT820428E (fi) |
RU (1) | RU2191772C2 (fi) |
SK (1) | SK282897B6 (fi) |
UA (1) | UA46020C2 (fi) |
WO (1) | WO1996030328A1 (fi) |
ZA (1) | ZA962275B (fi) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL119971A (en) * | 1997-01-07 | 2003-02-12 | Yissum Res Dev Co | Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids |
NZ503982A (en) * | 1997-12-12 | 2002-03-28 | Warner Lambert Co | Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus |
US6861555B2 (en) * | 2000-01-25 | 2005-03-01 | Warner-Lambert Company | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
SI1045691T1 (en) * | 1997-12-12 | 2005-04-30 | Warner-Lambert Company Llc | Statin-carboxyalkylether combinations |
US20030105154A1 (en) * | 2001-10-24 | 2003-06-05 | Bisgaier Charles Larry | Statin-carboxyalkylether combinations |
PL343851A1 (en) * | 1997-12-12 | 2001-09-10 | Warner Lambert Co | Antihyperlipidemic statin-lp(a) inhibitor combinations |
NZ505761A (en) * | 1998-01-28 | 2003-08-29 | Warner Lambert Co | Method for treating alzheimer's disease using plasma-triglceride level-lowering agents or agents that interfer with cholesterol ester synthesis |
KR20010079955A (ko) * | 1998-09-30 | 2001-08-22 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 카테테르 기재 혈관재개통술의 예방 및 지연 방법 |
ATE384035T1 (de) | 1999-04-01 | 2008-02-15 | Esperion Therapeutics Inc | Ether-verbindungen, zusammensetzungen und ihre verwendung |
EP1849760A1 (en) * | 1999-04-01 | 2007-10-31 | Esperion Therapeutics Inc. | Ether compounds, compositions, and uses thereof |
CN1395555A (zh) | 2000-01-25 | 2003-02-05 | 沃尼尔·朗伯公司 | 二羧酸醚钙、其制备方法、和用其治疗血管疾病和糖尿病的方法 |
US20040092574A1 (en) * | 2000-02-07 | 2004-05-13 | Bisgaier Charles Larry | Statin-Lp(a) inhibitor combinations |
PT1280522E (pt) * | 2000-04-26 | 2005-02-28 | Warner Lambert Co | Combinacao de eteres carboxialquilicos com anti-hipertensores e a utilizacao farmaceutica |
KR20030023698A (ko) * | 2000-07-14 | 2003-03-19 | 워너-램버트 캄파니 | 카르복시알킬에테르를 사용하여 섭식 장애를 치료하는 방법 |
CA2425121A1 (en) | 2000-10-11 | 2002-04-18 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
US20040122091A1 (en) * | 2000-10-11 | 2004-06-24 | Esperion Therapeutics, Inc. | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
CN101426763A (zh) | 2000-10-11 | 2009-05-06 | 埃斯佩里安医疗公司 | 用于胆固醇治疗和相关应用的硫化物和二硫化物化合物和组合物 |
US7304093B2 (en) * | 2000-10-11 | 2007-12-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
BRPI0114622B8 (pt) | 2000-10-11 | 2021-05-25 | Esperion Therapeutics Inc | composto, composição farmacêutica compreendendo o mesmo e uso do referido composto na preparação de composição farmacêutica |
WO2002030882A2 (en) * | 2000-10-11 | 2002-04-18 | Esperion Therapeutics, Inc. | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
US20030225123A1 (en) * | 2001-03-22 | 2003-12-04 | Auerbach Bruce Jeffrey | Antihypertensive agents and use |
US20040072903A1 (en) * | 2001-05-08 | 2004-04-15 | Auerbach Bruce Jeffrey | Carboxyalkylether-acat inhibitors combinations |
US20040192771A1 (en) * | 2001-10-11 | 2004-09-30 | Dasseux Jean-Louis Henri | Ether compounds and compositions for cholesterol management and related uses |
US20040204502A1 (en) * | 2001-10-11 | 2004-10-14 | Dasseux Jean-Louis Henri | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
US20050020694A1 (en) * | 2001-10-11 | 2005-01-27 | Dasseux Jean-Louis Henri | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
US20030236212A1 (en) * | 2002-04-10 | 2003-12-25 | Jean-Louis Dasseux | Functionalized long chain derivatives as acyl coenzyme-A mimics, compositions thereof, and methods of cholesterol management and related uses |
CN1678297A (zh) * | 2002-08-22 | 2005-10-05 | 沃纳-兰伯特公司 | 治疗骨关节炎的方法 |
US20040048910A1 (en) * | 2002-08-22 | 2004-03-11 | Bove Susan Elizabeth | Method of treating osteoarthritis |
AU2003266165A1 (en) * | 2002-09-13 | 2004-04-30 | Hossein Dovlatabadi | Methods and compositons for the use of d-malic acid to decrease serum triglyceride, cholesterol, and lipoprotein levels |
EP1572189A1 (en) * | 2002-11-15 | 2005-09-14 | Warner-Lambert Company LLC | Method of lowering crp and reducing systemic inflammation |
DK2404890T3 (en) * | 2003-01-23 | 2017-10-16 | Esperion Therapeutics Inc | Hydroxyl compounds and compositions for controlling cholesterol and related uses |
US20040229954A1 (en) * | 2003-05-16 | 2004-11-18 | Macdougall Diane Elaine | Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt |
WO2005002557A1 (en) * | 2003-07-03 | 2005-01-13 | Warner-Lambert Company Llc | Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof |
US20050026979A1 (en) * | 2003-07-31 | 2005-02-03 | Maha Ghazzi | Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
CA2543596A1 (en) * | 2003-11-07 | 2005-05-26 | Jj Pharma, Inc. | Hdl-boosting combination therapy complexes |
US20050192347A1 (en) * | 2003-12-23 | 2005-09-01 | Dasseux Jean-Louis H. | Urea and thiourea compounds and compositions for cholesterol management and related uses |
CA2549995C (en) | 2003-12-24 | 2011-11-15 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
WO2005068410A1 (en) * | 2003-12-24 | 2005-07-28 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
UY28951A1 (es) * | 2004-06-09 | 2006-01-31 | Avanir Pharmaceuticals | Pequenas moleculas para el tratamiento de hipercolesterolemia y enfermedades relacionadas |
UY28952A1 (es) * | 2004-06-09 | 2006-01-31 | Avanir Pharmaceuticals | Mediadores del transporte inverso de colesterol para el tratamiento de la hipercolesterolemia |
KR20070026598A (ko) * | 2004-06-09 | 2007-03-08 | 아바니르 파마슈티컬스 | 고지혈증 및 관련 질환의 치료를 위한 헤테로사이클 유도체 |
CA2584485C (en) * | 2004-10-20 | 2013-12-31 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
WO2007016525A2 (en) * | 2005-07-29 | 2007-02-08 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
WO2008018877A1 (en) * | 2006-08-11 | 2008-02-14 | Ssv Therapeutics, Inc. | Carnitine conjugates as dual prodrugs, methods of production and uses thereof |
DK2118074T3 (en) * | 2007-02-01 | 2014-03-10 | Resverlogix Corp | Compounds for the prevention and treatment of cardiovascular diseases |
CA2688111A1 (en) | 2007-05-23 | 2008-12-04 | Amcol International Corporation | Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal |
US7985727B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Apo A-I mimetic peptides and methods of treatment |
US8101565B2 (en) * | 2007-09-20 | 2012-01-24 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
US7985728B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
US8044021B2 (en) * | 2007-09-20 | 2011-10-25 | Abbott Cardiovascular Systems Inc. | Sustained release of apo A-I mimetic peptides and methods of treatment |
US9173890B2 (en) * | 2007-09-20 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
ES2532402T3 (es) | 2008-06-26 | 2015-03-26 | Resverlogix Corporation | Métodos de preparación de derivados de quinazolinona |
NZ594332A (en) | 2009-01-08 | 2013-09-27 | Resverlogix Corp | Compounds for the prevention and treatment of cardiovascular disease |
NZ755378A (en) | 2009-03-18 | 2022-07-29 | Resverlogix Corp | Novel quinazolinones and related compounds for use as anti-inflammatory agents |
US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
SG178447A1 (en) | 2009-09-03 | 2012-03-29 | Pfizer Vaccines Llc | Pcsk9 vaccine |
AU2011305610A1 (en) | 2010-09-20 | 2013-03-14 | Kareus Therapeutics, Sa | Methods and compositions for treatment of diabetes and dyslipidemia |
CN103442714B (zh) | 2010-10-18 | 2017-04-19 | 塞伦尼斯医疗控股有限公司 | 可用于胆固醇动员的化合物、组合物和方法 |
EP3170495B1 (en) | 2010-12-27 | 2023-04-26 | Gemphire Therapeutics Inc. | Gemcabene for treating pancreatitis |
WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
PT2773354T (pt) | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
EP2800564B1 (en) | 2012-01-06 | 2020-05-06 | NeuroBo Pharmaceuticals, Inc. | Compound for use in methods of reducing risk of cardiovascular disease |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
CA2895905A1 (en) | 2012-12-21 | 2014-06-26 | Zenith Epigenetics Corp. | Novel heterocyclic compounds as bromodomain inhibitors |
WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
SG11201609084QA (en) | 2014-05-02 | 2016-11-29 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
BR112017009876A2 (pt) * | 2014-11-14 | 2017-12-19 | Gemphire Therapeutics Inc | processos e intermediários para a preparação de éteres de dialcano terminados em ácido alfa,ômega-dicarboxílico |
CA2977308A1 (en) | 2015-03-13 | 2016-09-22 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
CN114099496A (zh) | 2015-03-13 | 2022-03-01 | 艾斯柏伦治疗公司 | 含etc1002和依泽替米贝的组合及治疗方法 |
MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
EP3370713A4 (en) * | 2015-11-06 | 2019-10-23 | Gemphire Therapeutics Inc. | TREATMENT OF MIXED DYSLIPIDEMIA |
WO2018165120A1 (en) * | 2017-03-06 | 2018-09-13 | Gemphire Therapeutics Inc. | Effect of carboxyalkylethers on obesity symptoms and lipodystropy |
TW201902471A (zh) * | 2017-04-18 | 2019-01-16 | 美商珍費爾醫療公司 | 賈卡賓尼(gemcabene)、其醫藥上可接受之鹽、彼等之組成物及使用彼等之方法 |
CA3144371A1 (en) | 2019-06-21 | 2020-12-24 | Esperion Therapeutics, Inc. | Methods of making bempedoic acid and compositions of the same |
US11098002B2 (en) | 2019-07-26 | 2021-08-24 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease |
WO2021262992A1 (en) | 2020-06-24 | 2021-12-30 | Neurobo Pharmaceuticals, Inc. | Gemcabene for treatment of cytokine storms and viral-induced inflammation |
US11730712B2 (en) | 2021-01-25 | 2023-08-22 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease |
EP4281058A2 (en) | 2021-01-25 | 2023-11-29 | Espervita Therapeutics, Inc. | Functionalized long-chain carboxylic acids, and their use for treatment of disease |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2466419A (en) * | 1948-02-07 | 1949-04-05 | Eastman Kodak Co | beta, beta'-oxydipropionic acids and process of preparation |
US3320079A (en) * | 1960-07-11 | 1967-05-16 | Eastman Kodak Co | Ether-acid polyester composition |
US3431298A (en) * | 1965-01-05 | 1969-03-04 | Asahi Chemical Ind | Process for the preparation of oxadicarboxylic acids |
US3674836A (en) * | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
US3930024A (en) * | 1969-09-02 | 1975-12-30 | Parke Davis & Co | Pharmaceutical compositions and methods |
BE755997A (fr) * | 1969-09-11 | 1971-03-10 | Bp Chem Int Ltd | Production d'acides dicarboxyliques |
US3742068A (en) * | 1970-04-17 | 1973-06-26 | G Moersch | Ethers of 2,2,9,9-tetramethyl-1,10-decanediol |
IT1168389B (it) * | 1981-05-06 | 1987-05-20 | Alfa Farmaceutici Spa | Derivati di alcandioli con attivita' ipolipidemizzante,metodi per la loro preparazione e composizioni farmaceutiche che li contengono |
DE3423166A1 (de) * | 1984-06-22 | 1986-01-02 | Epis S.A., Zug | Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
IL84953A (en) * | 1987-12-28 | 1992-01-15 | Bromine Compounds Ltd | 3,3'-oxy-bis((2,2'-di(bromomethyl)propanoic acid)derivatives,processes for their preparation and their use as flame retardant agents |
DE3814498A1 (de) * | 1988-04-29 | 1989-11-09 | Basf Ag | Verfahren zur herstellung von hydroxicarbonsaeureestern |
US5395917A (en) * | 1993-05-21 | 1995-03-07 | E. I. Du Pont De Nemours And Company | Polyimides from 4-(3-aminophenoxy)benzoic acid |
-
1995
- 1995-03-24 US US08/409,780 patent/US5648387A/en not_active Expired - Lifetime
-
1996
- 1996-02-05 PL PL96322407A patent/PL181673B1/pl not_active IP Right Cessation
- 1996-02-05 DE DE69608268T patent/DE69608268T2/de not_active Expired - Lifetime
- 1996-02-05 EE EE9700375A patent/EE03520B1/xx not_active IP Right Cessation
- 1996-02-05 PT PT96903794T patent/PT820428E/pt unknown
- 1996-02-05 NZ NZ302170A patent/NZ302170A/en unknown
- 1996-02-05 CN CN96193500A patent/CN1100747C/zh not_active Expired - Fee Related
- 1996-02-05 CZ CZ19972922A patent/CZ289556B6/cs not_active IP Right Cessation
- 1996-02-05 HU HU9801825A patent/HUP9801825A3/hu unknown
- 1996-02-05 DK DK96903794T patent/DK0820428T3/da active
- 1996-02-05 EP EP96903794A patent/EP0820428B1/en not_active Expired - Lifetime
- 1996-02-05 UA UA97105209A patent/UA46020C2/uk unknown
- 1996-02-05 AU AU47768/96A patent/AU692359B2/en not_active Ceased
- 1996-02-05 JP JP52934296A patent/JP3885115B2/ja not_active Expired - Lifetime
- 1996-02-05 CA CA002215233A patent/CA2215233C/en not_active Expired - Fee Related
- 1996-02-05 KR KR1019970706637A patent/KR100408612B1/ko not_active IP Right Cessation
- 1996-02-05 ES ES96903794T patent/ES2148733T3/es not_active Expired - Lifetime
- 1996-02-05 AT AT96903794T patent/ATE192732T1/de not_active IP Right Cessation
- 1996-02-05 WO PCT/US1996/001639 patent/WO1996030328A1/en active IP Right Grant
- 1996-02-05 SK SK1286-97A patent/SK282897B6/sk unknown
- 1996-02-05 RU RU97118420/04A patent/RU2191772C2/ru not_active IP Right Cessation
- 1996-03-20 ZA ZA962275A patent/ZA962275B/xx unknown
-
1997
- 1997-02-25 US US08/806,580 patent/US5783600A/en not_active Expired - Lifetime
- 1997-02-25 US US08/805,533 patent/US5750569A/en not_active Expired - Lifetime
- 1997-02-25 US US08/806,582 patent/US5756544A/en not_active Expired - Lifetime
- 1997-09-17 FI FI973713A patent/FI973713A/fi not_active IP Right Cessation
- 1997-09-23 NO NO974397A patent/NO307878B1/no not_active IP Right Cessation
- 1997-10-24 BG BG101993A patent/BG63534B1/bg unknown
-
1998
- 1998-09-04 HK HK98110440A patent/HK1009438A1/xx not_active IP Right Cessation
-
2000
- 2000-08-02 GR GR20000401806T patent/GR3034109T3/el not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI973713A (fi) | Karboksi- tai tetratsolipääteryhmiä sisältävät dialkyylieetterit | |
AU9555998A (en) | Multi-layered wound dressing | |
DE69831504T2 (de) | Orale verabreichungsform enthaltend einen protonenpumpeninhibitor (z.b.pantoprazole) | |
AR001440A1 (es) | Nuevos taxoides, su preparación y composiciones farmacéuticas que los contienen. | |
NO20056021L (no) | Anvendelse av CS-866 til fremstilling av et medikament | |
ZA967948B (en) | Craps qualified by blackjack. | |
AU4298596A (en) | Protracted glp-1 compositions | |
AU2307695A (en) | High solubility multicomponent inclusion complexes consisting of an acidic drug, a cyclodextrin and a base | |
US5690869C1 (en) | Use of a polymer material on the basis of modified hydrocolloids as covering material | |
FI951511A (fi) | IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon | |
EP0858262A4 (en) | THROMBIN INHIBITORS | |
AU1081695A (en) | The use of an ester of inositoltrisphosphate for the preparing of medicaments | |
AU3850100A (en) | Placing unit for a human being | |
DK0869785T3 (da) | 4-Hydroxycoumarin-3-carboxyamider til behandling af ikke-insulinafhængig diabetes mellitus | |
DE69407593T2 (de) | Polyisocyanatzusammensetzung | |
TR199701115T1 (xx) | B�ceklerle m�cadele i�in yeni y�ntem. | |
ES2163503T3 (es) | Compuesto ge3. | |
DE69717147D1 (en) | Thrombin inhibitoren | |
NO975211L (no) | Anordning for beskyttelse av telekommunikasjonsutstyr | |
UA18745A (uk) | Скло для світлофільтра |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MA | Patent expired |